.jpg)
1 hour ago
2
Article content
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company’s long-term growth objectives.
Article content
Article content
Article content
The strategic review process will evaluate a range of alternatives that may strengthen the Company’s position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
revyve® Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray have both received FDA 510(k) clearance in the United States and Health Canada approval. Commercial activities in both the US and Canada commenced in 2026 with the addition of key senior business development personnel.
Article content
Philip Renaud, Chairman of Kane Biotech, commented: “Over the past several years, Kane has built a differentiated position in biofilm science and advanced wound care while achieving important commercial and clinical milestones. The Board believes this is an appropriate time to undertake a disciplined review of strategic opportunities that may strengthen the Company’s position and enhance shareholder value. We are pleased to work with DNA Advisors as we evaluate potential opportunities and engage with parties that may support the next stage of Kane’s development.”
Article content
Article content
Dr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, added: “We remain focused on executing our commercial objectives while simultaneously evaluating initiatives that have the potential to create additional value for shareholders. Kane has established a strong foundation through its scientific expertise, intellectual property portfolio, expanding commercial activities, and growing market awareness of biofilm management in wound care. This review process is intended to ensure that the Company is pursuing the opportunities that best position Kane for long-term success.”
Article content
There can be no assurance that the strategic review process will result in any specific transaction or outcome. Kane has not established a timetable for completion of the review process and does not intend to disclose developments unless and until the Board of Directors has approved a specific course of action or disclosure is otherwise required by applicable securities laws.
Article content
About Kane Biotech Inc. (TSX-V:KNE)
Article content
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
English (US)